Memantine: A review of its use in Alzheimer's disease

Drugs

Volumn 66, Issue 11, 2006, Pages 1515-1534

  Robinson, Dean M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; CALCIUM CHANNEL; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; DIAZEPAM; DIZOCILPINE; DONEPEZIL; EPOXIDE HYDROLASE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; MAGNESIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENCYCLIDINE; PLACEBO; TAMOXIFEN;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; BEHAVIOR; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG UTILIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENINGOENCEPHALITIS; META ANALYSIS; NEUROPROTECTION; REVIEW; STEADY STATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGENTS; HUMANS; MEMANTINE; TREATMENT OUTCOME;

EID: 33747423612     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666110-00015     Document Type: Review

References (105)

1. Farlow MR. NMDA receptor antagonists: a new therapeutic approach for Alzheimer's disease. Geriatrics 2004 Jun; 59 (6): 22-7
2. Cummings JL. Alzheimer's disease. N Engl J Med 2004 Jul 1; 351 (1): 56-67
3. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995 May 3; 273 (17): 1354-9
4. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989 Nov 10; 262 (18): 2551-6
5. Li L, Sengupta A, Haque N, et al. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004 May 21; 566 (1-3): 261-9
6. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003 Fall; 9 (3): 275-308
7. Floden AM, Li S, Combs CK. β-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors. J Neurosci 2005 Mar 9; 25 (10): 2566-75
8. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 1999; 14 (1): 3-47
9. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 2004 Dec; 6 (6 Suppl.): S61-74
10. Forest Laboratories Inc. Prescribing information: Namenda™ tablets (memantine hydrochloride) [online]. Available from URL: http://www.frx.com/pi/ namenda_pi.pdf [Accessed 2005 Feb 15]
11. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006. CD003154; 2 [online]. Available from URL: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003154/ pdf_fs.html [Accessed 2006 Jun 6]
12. Jarvis B, Figgitt D. Memantine. Drugs Aging 2003; 20 (6): 465-76
13. Winblad B, Jelic V. Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry 2003 Sep; 18 Suppl. 1: S41-6
14. US Department of Health and Human Services. Memantine approval letter [online]. Oct 2003. Available from: http://www.fda.gov/cder/foi/appletter/2003/ 21487ltr.pdf [Accessed 2005 Mar].
15. European Medicines Agency. Ebixa. European Public Assessment Report. [online]. Jul 2002. Available from: http://www.emea.eu.int/humandocs/PDFs/EPAR/ ebixa [Accessed 22 Feb 2005].
16. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003 Sep; 18 Suppl. 1: S23-32
17. Chen H-SV, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992 Nov; 12 (11): 4427-36
18. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999 Jun; 38 (6): 735-67
19. Chen H-SV, Wang YF, Rayudu PV, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998 Oct; 86 (4): 1121-32
20. Blanpied TA, Boeckman FA, Aizenman E, et al. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997 Jan; 77 (1): 309-23
21. Parsons CG, Gruner R, Rozental J, et al. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5- dimethyladamantan). Neuropharmacology 1993 Dec; 32 (12): 1337-50
22. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl- cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001 Jun 22; 306 (1-2): 81-4
23. Marvanová M, Lakso M, Pirhonen J, et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001 Sep; 18 (3): 247-58
24. Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993 Jun 4; 613 (1): 143-8
25. Erd̈o SL, Schäfer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991 Jun 6; 198 (2-3): 215-7
26. Krieglstein J, Lippert K, Pöch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology 1996; 35 (12): 1737-42
27. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993 Apr; 33 (4): 403-7
28. Seif el Nasr M, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990 Aug 21; 185 (1): 19-24
29. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997 Feb; 83 (1-2): 129-33
30. Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm 1995; 46 Suppl.: 117-30
31. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1-40). Brain Res 2002 Dec 20; 958 (1): 210-21
32. Minkeviciene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004 Jun 10; 311 (2): 677-82
33. Potkin SG, McDonald S, Gergel I, et al. Memantine monotherapy increases brain metabolism (PET) and effectively treats mild to moderate Alzheimer's disease [abstract no. P02.292]. 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20-24; Paris. Int J Neuropsychopharmacol 2004; 7 (Suppl. 1): S380-1.
34. Schugens MM, Egerter R, Daum I, et al. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett 1997 Mar 7; 224 (1): 57-60
35. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem 2001; 8 (1): 20-5
36. Schwenkreis P, Witscher K, Janssen F, et al. Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 1999 Aug 6; 270 (3): 137-40
37. Dinse HR, Ragert P, Pleger B, et al. Pharmacological modulation of perceptual learning and associated cortical reorganization. Science 2003 Jul 4; 301 (5629): 91-4. Plus supporting material [online]. Available from URL: http://www.sciencemag.org/cgi/data/301/5629/91/DC1/ [Accessed 2005 Feb 15]
38. Schulz H, Jobert M, Coppola R, et al. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology 1996; 33 (1): 32-40
39. Tandon V. US Food and Drug Administration Center for Drug Evaluation and Research approval package for application number 21-487. Clinical pharmacology and biopharmaceutics review: memantine [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2003/21-487_Namenda.htm [Accessed 2005 Feb 18]
40. Wesemann W, Sturm G, Funfgeld EW. Distribution of metabolism of the potential anti-Parkinson drug memantine in the human. J Neural Transm Suppl 1980; (16): 143-8
41. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995 Aug 4; 195 (2): 137-9
42. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006 Jan; 79 (1): 134-43
43. Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol 2004 Oct; 60 (8): 583-9
44. Wenk GL, Quack G, Moebius H-J, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000 Feb 11; 66 (12): 1079-83
45. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004 Sep; 38 (9): 1389-94
46. Forest Laboratories Inc. Forest Laboratories Clinical Trials Registry: study no. MEM-MD-01 [online]. Available from URL: http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/ SCSR_MEM-MD-01_final.pdf [Accessed 2005 Jun 8]
47. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 Apr 3; 348 (14): 1333-41
48. Winblad B, Graham SM, Lee GS, et al. Efficacy and tolerability of memantine in nursing home patients with moderate-to-severe dementia of the Alzheimer's type [poster no. 64]. 17th Annual Meeting of the American Association for Geriatric Psychiatry; 2004 Feb 21-24; Baltimore (MD)
49. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan 21; 291 (3): 317-24
50. Bakchine S, Pascual-Gangnant L, Loft H. Results of a randomised, placebo-controlled 6-month study in the treatment of mild-to-moderate Alzheimer's Disease in Europe [poster no. P2087]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
51. Forest Laboratories Inc. Forest Laboratories Clinical Trials Registry: study no. MEM-MD-12 [online]. Available from URL: http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/ SCSR_MEM-MD-12_final.pdf [Accessed 2005 Jun 8]
52. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006 Aug; 14 (8): 704-15
53. Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease [poster no. 81]. New Clinical Drug Evaluation Unit 45th Annual Meeting; 2005 Jun 6-9; Boca Raton (FL)
54. 9M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14 (2): 135-46
55. Winblad B, Möbius HJ, Stöffler A. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neural Transm 2002; 62 Suppl.: 217-25
56. LU-99679 protocol, study report (data on file) Denmark: H. Lundbeck, A/S. 2005
57. Mani RB. US Food and Drug Administration Center for Drug Evaluation and Research approval package for application number 21-487. Medical reviews: memantine [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2003/21- 487_Namenda.htm [Accessed 2005 Feb 18]
58. Tocco M, Olin JT, Feldman HH, for the MEM-MD-02 Study Group. Maintenance of response to memantine treatment in moderate to severe Alzheimer's disease patients receiving stable donepezil treatment [poster no. 23]. 19th Annual Meeting of the American Association for Geriatric Psychiatry; 2006 Mar 10-13; San Juan
59. Feldman H, Schmitt FA, Doraiswamy PM, et al. Memantine and individual activities of daily living in moderate to severe Alzheimer's disease [poster no. P02.092]. 57th Annual Meeting of the American Academy of Neurology; 2005 Apr 9-16; Miami Beach (FL)
60. Wilkinson D, Andersen HF. Prevention of worsening of clinical symptoms in moderate to severe Alzheimer's disease in patients treated with memantine [poster]. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2006 April 19-22; Geneva
61. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials [poster]. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2006 April 19-22; Geneva
62. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005 Apr 25; 20 (5): 459-64
63. Cummings JL, Schneider E, Tariot PN, et al. Behavioural effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006 Jul 11; 67: 57-63
64. Rive B, Vercelletto M, Damier FD, et al. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2004 May; 19 (5): 458-64
65. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004 Sep 27; 19 (10): 919-25
66. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63 (1): 49-54
67. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 Jul; 34 (7): 939-44
68. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994
69. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005; 23 (2): 193-206
70. Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005 Jun; 3 (2): 77-86
71. National Institute for Clinical Excellence. Appraisal Consultation Document: Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review) [online]. Available from URL: http://www.nice.org.uk/page. aspx?o=245912 [Accessed 2005 Mar 1]
72. Neumann PJ. Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Pharmacoeconomics 2005; 23 (6): 537-41
73. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006 Jan; 10 (1): 1-176
74. Kirby J, Green C, Loveman E, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging 2006; 23 (3): 227-40
75. Francois C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin Drug Investig 2004; 24 (7): 373-84
76. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's Disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21 (9): 607-20
77. European Medicines Agency. European Public Assessment Report: procedural steps taken and scientific information after authorisation [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ebixa/ebixa.htm [Accessed 2006 Jun 22]
78. European Medicines Agency. Ebixa. European Public Assessment Report: summary of product characteristics. [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ebixa/ebixa.htm [Accessed 2006 Jul 25]
79. Merz Pharmaceuticals. Summary of product characteristics. Axura 10 mg film coated tablets [online]. Available from URL: http://download.merz.de/axura- info/pdf/memantine_product_characteristics.pdf#page=9 [Accessed 2006 May 1]
80. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003 Apr-Jun; 17 (2): 63-7
81. Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21 (5): 327-40
82. Maslow K, Selstad J, Denman SJ. Guidelines and care management issues for people with Alzheimer's disease and other dementias. Dis Manage Health Outcomes 2002; 10 (11): 693-706
83. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer's disease. How can we manage the costs? Pharmacoeconomics 2000 Sep; 18 (3): 215-23
84. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 2003 Apr; 43 (2): 158-64
85. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997 Oct 22-29; 278 (16):1363-71
86. Smith GB. Case management guideline: Alzheimer disease and other dementias. Lippincotts Case Manag 2002 Mar-Apr; 7 (2): 77-84
87. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998 Sep; 88 (9): 1337-42
88. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003 Apr; 58 (4): 331-53
89. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002 Jun 1; 65 (11): 2263-72
90. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002 Jun 15; 65 (12): 2525-34
91. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11; 158 (9): 1021-31
92. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001 Aug 28; 57 (4): 613-20
93. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002; 16 (12): 811-24
94. Roses AD, Pangalos MN. Drug development and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11 (2): 123-30
95. Windisch M, Hutter-Paier B, Schreiner E. Current drugs and future hopes in the treatment of Alzheimer's disease. J Neural Transm 2002; 62 Suppl.: 149-64
96. Michaelis ML. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 2003; 304 (3): 897-904
97. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997 Apr 24; 336 (17): 1216-22
98. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005 Jun 9; 352 (23): 2379-88
99. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003 Jul 8; 61 (1): 46-54
100. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002 Nov; 17 (6): 297-305
101. Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002 Jul; 33 (7): 1834-9
102. Möbius HJ, Stoffler A. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis 2002; 13 Suppl. 2: 61-6
103. Pass MD, Shua-Haim JR, Patel P, et al. Safety, tolerability, and caregiver's impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer's disease [abstract no. P1-392]. 9th International Conference on Alzheimer's Disease and Related Disorders; 2004 Jul 17-22; Philadelphia (PA)
104. Shua-Haim JR, Pass MD, Patel S, et al. Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease [abstract no. P1-377]. 9th International Conference on Alzheimer's Disease and Related Disorders; 2004 Jul 17-22; Philadelphia (PA)
105. US National Institutes of Health. An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/ NCT00097916 [Accessed 2005 Mar 4]